Cannabinoid receptors as novel targets for the treatment of melanoma

@article{Blazquez2006CannabinoidRA,
  title={Cannabinoid receptors as novel targets for the treatment of melanoma},
  author={Cristina Blázquez and Arkaitz Carracedo and L. Barrado and Pedro Jos{\'e} Real and Jos{\'e} Luis Fern{\'a}ndez‐Luna and Guillermo Velasco and Marcos Malumbres and Manuel Guzm{\'a}n},
  journal={The FASEB Journal},
  year={2006},
  volume={20},
  pages={E2199 - E2208}
}
Melanoma causes the greatest number of skin cancer‐related deaths worldwide. Despite intensive research, prevention and early detection are the only effective measures against melanoma, so new therapeutic strategies are necessary for the management of this devastating disease. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors… 

Cannabinoids and their derivatives in struggle against melanoma

It was pointed out that cannabinoids may be potentially useful in the melanoma therapy, but due to limited amount of data, great variety of cannabinoids available and lack of clinical trials, further studies are required to determine an exact role of cannabinoids in the treatment of melanoma.

Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.

It is suggested that THC activates noncanonical autophagy-mediated apoptosis of melanoma cells, suggesting that cytotoxic autophile induction with Sativex warrants clinical evaluation for metastatic disease.

Revisiting CB1 Receptor as Drug Target in Human Melanoma

The studies revealed that systemic administration of a stable CB1 agonist, ACEA, into SCID mice specifically inhibited liver colonization of human melanoma cells, suggesting the endocannabinoid-CB1 receptor system may offer a novel target.

Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells.

  • S. CarpiS. Fogli P. Nieri
  • Biology
    Toxicology in vitro : an international journal published in association with BIBRA
  • 2017

The pharmacological basis for application of cannabidiol in cancer chemotherapy

The pharmacological basis for therapeutic application of CBD is constructed on the scientific data for its antitumor activity, extensively provided studies in vitro and in vivo in animal tumor models, and available data on the safety profile of clinically approved CBD products.

Cannabinoids: a new hope for breast cancer therapy?

Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

Evidence from in vivo studies assessing the use of cannabinoids for treatment of melanoma revealed cannabinoids, individually or combined, reduced tumor growth and promoted apoptosis and autophagy in melanoma cells.

Cannabinoids as Potential Antitumoral Agents in Pancreatic Cancer

The fair safety profile of THC, together with its possible growth-inhibiting action on tumor cells, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids in other types of tumors such as pancreatic adenocarcinomas.

Anticancer activity of anandamide in human cutaneous melanoma cells.

Cannabinoids as anticancer drugs: current status of preclinical research

This review provides an up-to-date overview of the potential of cannabinoids as inhibitors of tumour growth and spread as demonstrated in preclinical studies.
...

References

SHOWING 1-10 OF 50 REFERENCES

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.

It is shown that the CB(1) and theCB(2) receptor are expressed in normal skin and skin tumors of mice and humans and support a new therapeutic approach for the treatment of skin tumors.

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

It is shown that local administration of the selective CB(2) agonist JWH-133 at 50 microg/day to Rag-2(-/-) mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells, and showed that selective activation of the CB( 2) receptor signaled apoptosis via enhanced ceramide synthesis de novo.

Deregulated Akt3 Activity Promotes Development of Malignant Melanoma

It is reported that selective activation of the Akt3 protein promotes cell survival and tumor development in 43 to 60% of nonfamilial melanomas and provides new therapeutic opportunities for patients in the advanced stages of this disease.

Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas

Cannabinoids inhibit tumor angiogenesis in mice, but the mechanism of their antiangiogenic action is still unknown. Because the vascular endothelial growth factor (VEGF) pathway plays a critical role

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells

It is discovered that Δ9-THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2 and was also more potent at inhibiting the proliferation of G BM cells compared to WIN55,212,2.

Inhibition of tumor angiogenesis by cannabinoids

It is shown that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays.

Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

It is shown that intratumoral administration of Δ9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2.

Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth

  • M. BifulcoC. Laezza V. Di Marzo
  • Biology, Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2001
The data suggest that Met‐F‐AEA inhibits ras oncogene‐dependent tumor growth in vivo through CB1 cannabinoid receptors; and responsiveness of FRTL‐5 cells to endocannabinoids depends on whether or not they are transformed by K‐ras.

A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

The fair safety profile of THC, together with its possible antiproliferative action on tumour cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence. These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide